Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2025)

Vivos Therapeutics has reported Non-Current Debt over the past 3 years, most recently at $469000.0 for Q4 2025.

  • Quarterly Non-Current Debt changed N/A to $469000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $469000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $469000.0 for FY2025, N/A changed from the prior year.
  • Non-Current Debt was $469000.0 for Q4 2025 at Vivos Therapeutics, down from $8.4 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $8.4 million in Q3 2025 and troughed at $105906.0 in Q1 2021.